Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pihlajalinna OyjFRA:38P 72 Debt-to-EBITDA is 3.21 as of Jun. 2026, which is 2% below its 10-year median of 3.27. GuruFocus rates FRA:38P with a GF Score™ of 72/100 and a GF Value™ of €9.05 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Pihlajalinna Oyj ranks better than 51.47% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pihlajalinna Oyj's Debt-to-EBITDA or its related term are showing as below:
FRA:38P'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.77 Med: 3.27 Max: 7.43
Current: 2.15
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pihlajalinna Oyj was 7.43. The lowest was 1.77. And the median was 3.27.
FRA:38P's Debt-to-EBITDA is ranked better than 51.47% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs FRA:38P: 2.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pihlajalinna Oyj Debt-to-EBITDA Related Terms
Pihlajalinna Oyj Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pihlajalinna Oyj's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:38P vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Pihlajalinna Oyj's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pihlajalinna Oyj Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pihlajalinna Oyj's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pihlajalinna Oyj's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Pihlajalinna Oyj (FRA:38P) has a Debt-to-EBITDA of 3.21 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pihlajalinna Oyj. This is near median its historical median of 3.27. Over the past decade, Pihlajalinna Oyj's Debt-to-EBITDA has ranged from 1.77 to 7.43. According to the industry distribution chart, Pihlajalinna Oyj ranks #231 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 48.5%.
Is Pihlajalinna Oyj's Debt-to-EBITDA too high?
Pihlajalinna Oyj's current Debt-to-EBITDA of 3.21 is near median its 10-year median of 3.27. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 7.43. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Pihlajalinna Oyj's value of 3.21 is 46.2% above this industry median. Based on the distribution chart, Pihlajalinna Oyj ranks #231 out of 476 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pihlajalinna Oyj has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pihlajalinna Oyj's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Pihlajalinna Oyj ranks #231 out of 476 companies for Debt-to-EBITDA. This puts Pihlajalinna Oyj in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Pihlajalinna Oyj's value of 3.21 is 46.2% above this benchmark. Historically, Pihlajalinna Oyj's own Debt-to-EBITDA has ranged from 1.77 to 7.43 over the past decade. While the company's 10-year median is 3.27 vs. the industry median of 2.20, Pihlajalinna Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pihlajalinna Oyj's current Debt-to-EBITDA of 3.21 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pihlajalinna Oyj. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pihlajalinna Oyj's current Debt-to-EBITDA is 3.21, which is near median its own 10-year median of 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pihlajalinna Oyj stock overvalued right now?
Based on GuruFocus' analysis, Pihlajalinna Oyj (FRA:38P) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.05, compared to a current price of €10.26 — trading 13.4% above its estimated fair value. The current Debt-to-EBITDA is 3.21, which is near median its 10-year median of 3.27 and 46.2% above the Healthcare Providers & Services industry median of 2.20. Pihlajalinna Oyj's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pihlajalinna Oyj (FRA:38P), the current Debt-to-EBITDA is 3.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pihlajalinna Oyj (FRA:38P) Overvalued in 2026?
Based on GuruFocus' analysis, Pihlajalinna Oyj stock appears to be overvalued.
The current stock price of €10.26 is trading 13.4% above its estimated GF Value™ of €9.05.
GuruFocus considers Pihlajalinna Oyj to be Modestly Overvalued.
Key valuation signals for FRA:38P:
Debt-to-EBITDA: 3.21 (near median its 10-year median of 3.27)
GF Value™: €9.05 vs. price of €10.26 (13.4% above fair value)
Industry Position: 46.2% above the Healthcare Providers & Services median (#231 of 476)
No single metric tells the full story. See the FRA:38P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pihlajalinna Oyj is a private social and healthcare service providers in Finland. It provides comprehensive, high-quality services through private clinics, hospitals, remote channels, occupational healthcare, and tailored social and healthcare solutions for the public sector. It has two reportable segments: Private Healthcare Services and Public Services. The Private Healthcare Services operating segment consists of private clinic, diagnostics, hospital, occupational healthcare, remote and fitness center services. The Public Services operating segment consists of social and healthcare services produced for the public sector, which include outsourcing and housing services, mainly remotely produced responsible doctor services, as well as a wide range of staffing and recruitment services.
72GF Score
Get the complete analysis for FRA:38P
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:38P has been successfully added to your 
